Lv2
200 积分 2021-11-02 加入
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
2个月前
已完结
Epithelial alarmins TSLP, IL-33, and IL-25 in asthma pathogenesis: mechanistic roles and therapeutic implications
2个月前
已完结
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
2个月前
已完结
Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases
2个月前
已完结
CXCR6 as a novel therapeutic target in allergic asthma
5个月前
已完结
The role of the CXCR6/CXCL16 axis in the pathogenesis of fibrotic disease
5个月前
已完结
Role of the CXCR6/CXCL16 axis in autoimmune diseases
5个月前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
7个月前
已完结
Research progress in OX40/OX40L in allergic diseases
8个月前
已完结
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
8个月前
已完结
皖公网安备34019202002308
